When it comes to distribution of the abortion drug mifepristone, the U.S. Food and Drug Administration (FDA) has been asleep at the switch. Despite comprehensive data showing higher rates of complications and emergency room visits from chemical abortion, the abortion pill has been feted by the corporate media, promoted as “safe” by President Joe Biden, and subjected to increasingly lax oversight by the FDA.
All of this makes a little-heralded recent story in Politico even more interesting. An anonymous FDA source warns against the intensifying abortion industry campaign to give abortion pills to women and girls who are not pregnant.
